{"entity":{"id":"nct03971409","kind":"trial","name":"Avelumab combinations in advanced TNBC","aka":["Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer"],"tldr":"This study tests avelumab with different drug combinations in advanced triple-negative breast cancer. Some groups receive treatment intended to stimulate the immune system before the main combination.","summary":"This study tests avelumab with different drug combinations in advanced triple-negative breast cancer. Some groups receive treatment intended to stimulate the immune system before the main combination.\n\nInterventional study registered as NCT03971409, sponsored by Laura Huppert, MD, BA. Registry phase: 2. Registry enrollment is 145 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT03971409","url":"https://clinicaltrials.gov/study/NCT03971409"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT03971409"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["avelumab","binimetinib","sacituzumab-govitecan","utomilumab"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03971409","phase":"2","setting":"Stage IV or unresectable recurrent triple-negative breast cancer","sponsor":"Laura Huppert, MD, BA","participation":[{"nct":"NCT03971409","source":"https://clinicaltrials.gov/study/NCT03971409","fetchedAt":"2026-10-10T20:54:20.296495Z","studySha256":"3fa049299222fdfb5ea522008a1ac72d47ddbb077fcd6241a95934a9a1b33f22","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-17","leadSponsor":"Laura Huppert, MD, BA","collaboratorCount":7,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":145,"enrolmentType":"ACTUAL","siteCount":12,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2019-07-08","startedType":"actual","enrolled":145,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03971409/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"},{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}